Pathway Genomics Introduces BRCA1/2 Genetic Test with One for One Program
Proquest LLC |
Pathway Genomics said that it has launched BRCATrue, a next- generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer.
BRCATrue has a sensitivity of greater than 99.99 percent and the broadest coverage across BRCA1/2 in the industry, the Company noted in its release.
To enhance the accessibility of this genetic test, Pathway Genomics said that it has developed the BRCA One for One program - for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to
"Pathway's mission is to ensure that people in need receive genetic testing regardless of their economic or insurance status," said
"One out of every eight women will be affected by breast cancer in her lifetime," said
More Information:
((Comments on this story may be sent to [email protected]))
Copyright: | (c) 2014 ProQuest Information and Learning Company; All Rights Reserved. |
Wordcount: | 245 |
Fitzroy Health Acquires RJ Health Systems
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News